XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenues $ 28,231 $ 26,280
Operating expenses:    
Research and development 58,584 56,434
General and administrative 14,908 16,148
Total operating expenses 73,492 72,582
Loss from operations (45,261) (46,302)
Interest and other income, net 1,342 625
Loss before income taxes (43,919) (45,677)
Income tax expense 58 262
Net loss (43,977) (45,939)
Net loss attributable to non-controlling interest 0 (6)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (43,977) $ (45,933)
Earnings per share, basic (in dollars per share) $ (0.30) $ (0.32)
Earnings per share, diluted (in dollars per share) $ (0.30) $ (0.32)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 146,218 143,112
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 146,218 143,112